<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Dias J</submitter><funding>National Institute for Health Research (NIHR)</funding><pagination>1499-1510</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC7616701</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>391(16)</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>Treatments for Dupuytren's contracture include limited fasciectomy and collagenase injection. Comparisons of the effectiveness of these treatments have been limited.&lt;h4>Methods&lt;/h4>We performed an unblinded, multicenter, pragmatic, two-group, randomized, controlled noninferiority trial comparing collagenase injection with limited fasciectomy in persons with moderate Dupuytren's contracture. The primary outcome was the score on the Patient Evaluation Measure-Hand Health Profile (PEM), a questionnaire for assessing hand health as reported by the patient, at 1 year after treatment. Scores on the PEM range from 0 to 100, with higher scores indicating worse outcomes. The prespecified noninferiority margin was 6 points.&lt;h4>Results&lt;/h4>A total of 672 persons (336 per group) were assigned to receive collagenase injection or to undergo limited fasciectomy. The primary analysis included 599 persons: 314 in the collagenase group and 285 in the limited-fasciectomy group. The mean score on the PEM at 1 year was 17.8 among the 284 patients with available data in the collagenase group and 11.9 among the 250 patients with available data in the limited-fasciectomy group (estimated difference, 5.9 points; 95% confidence interval [CI], 3.1 to 8.8; one-sided P = 0.49 for noninferiority). Among the patients with available data (229 patients in the collagenase group and 197 patients in the limited-fasciectomy group), the estimated difference in the mean score on the PEM at 2 years was 7.2 points (95% CI, 4.2 to 10.9). Moderate or severe complications of treatment occurred in 1.8% of the patients in the collagenase group and in 5.1% of those in the limited-fasciectomy group; recurrent contracture resulted in reintervention in 14.6% and 3.4%, respectively.&lt;h4>Conclusions&lt;/h4>Collagenase injection was not noninferior to limited fasciectomy with respect to the score on the PEM at 1 year after treatment. (Funded by the National Institute for Health and Care Research Health Technology Assessment Programme; DISC ISRCTN Registry number ISRCTN18254597.).</pubmed_abstract><journal>The New England journal of medicine</journal><pubmed_title>Collagenase Injection versus Limited Fasciectomy for Dupuytren's Contracture.</pubmed_title><pmcid>PMC7616701</pmcid><funding_grant_id>15/102/04</funding_grant_id><pubmed_authors>Arundel C</pubmed_authors><pubmed_authors>Torgerson D</pubmed_authors><pubmed_authors>Johnson N</pubmed_authors><pubmed_authors>Wu Q</pubmed_authors><pubmed_authors>Armaou M</pubmed_authors><pubmed_authors>Warwick D</pubmed_authors><pubmed_authors>Watson M</pubmed_authors><pubmed_authors>Knowlson CN</pubmed_authors><pubmed_authors>Bainbridge L</pubmed_authors><pubmed_authors>Leighton P</pubmed_authors><pubmed_authors>Tharmanathan P</pubmed_authors><pubmed_authors>Brady S</pubmed_authors><pubmed_authors>Hewitt CE</pubmed_authors><pubmed_authors>Keding A</pubmed_authors><pubmed_authors>James S</pubmed_authors><pubmed_authors>Craigen M</pubmed_authors><pubmed_authors>Jones J</pubmed_authors><pubmed_authors>Flett LG</pubmed_authors><pubmed_authors>Welch C</pubmed_authors><pubmed_authors>Cooke J</pubmed_authors><pubmed_authors>Dias J</pubmed_authors></additional><is_claimable>false</is_claimable><name>Collagenase Injection versus Limited Fasciectomy for Dupuytren's Contracture.</name><description>&lt;h4>Background&lt;/h4>Treatments for Dupuytren's contracture include limited fasciectomy and collagenase injection. Comparisons of the effectiveness of these treatments have been limited.&lt;h4>Methods&lt;/h4>We performed an unblinded, multicenter, pragmatic, two-group, randomized, controlled noninferiority trial comparing collagenase injection with limited fasciectomy in persons with moderate Dupuytren's contracture. The primary outcome was the score on the Patient Evaluation Measure-Hand Health Profile (PEM), a questionnaire for assessing hand health as reported by the patient, at 1 year after treatment. Scores on the PEM range from 0 to 100, with higher scores indicating worse outcomes. The prespecified noninferiority margin was 6 points.&lt;h4>Results&lt;/h4>A total of 672 persons (336 per group) were assigned to receive collagenase injection or to undergo limited fasciectomy. The primary analysis included 599 persons: 314 in the collagenase group and 285 in the limited-fasciectomy group. The mean score on the PEM at 1 year was 17.8 among the 284 patients with available data in the collagenase group and 11.9 among the 250 patients with available data in the limited-fasciectomy group (estimated difference, 5.9 points; 95% confidence interval [CI], 3.1 to 8.8; one-sided P = 0.49 for noninferiority). Among the patients with available data (229 patients in the collagenase group and 197 patients in the limited-fasciectomy group), the estimated difference in the mean score on the PEM at 2 years was 7.2 points (95% CI, 4.2 to 10.9). Moderate or severe complications of treatment occurred in 1.8% of the patients in the collagenase group and in 5.1% of those in the limited-fasciectomy group; recurrent contracture resulted in reintervention in 14.6% and 3.4%, respectively.&lt;h4>Conclusions&lt;/h4>Collagenase injection was not noninferior to limited fasciectomy with respect to the score on the PEM at 1 year after treatment. (Funded by the National Institute for Health and Care Research Health Technology Assessment Programme; DISC ISRCTN Registry number ISRCTN18254597.).</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 Oct</publication><modification>2025-04-04T23:47:29.562Z</modification><creation>2025-04-04T23:47:29.562Z</creation></dates><accession>S-EPMC7616701</accession><cross_references><pubmed>39383454</pubmed><doi>10.1056/NEJMoa2312631</doi></cross_references></HashMap>